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Background and purpose: Severe acute mucositis commonly results from head and neck (chemo)radio-
therapy. A predictive model of mucositis could guide clinical decision-making and inform treatment
planning. We aimed to generate such a model using spatial dose metrics and machine learning.
Materials and methods: Predictive models of severe acute mucositis were generated using radiotherapy
dose (dose–volume and spatial dose metrics) and clinical data. Penalised logistic regression, support vec-
tor classification and random forest classification (RFC) models were generated and compared. Internal
validation was performed (with 100-iteration cross-validation), using multiple metrics, including area
under the receiver operating characteristic curve (AUC) and calibration slope, to assess performance.
Associations between covariates and severe mucositis were explored using the models.
Results: The dose–volume-based models (standard) performed equally to those incorporating spatial
information. Discrimination was similar between models, but the RFCstandard had the best calibration.
The mean AUC and calibration slope for this model were 0.71 (s.d. = 0.09) and 3.9 (s.d. = 2.2), respectively.
The volumes of oral cavity receiving intermediate and high doses were associated with severe mucositis.
Conclusions: The RFCstandard model performance is modest-to-good, but should be improved, and requires
external validation. Reducing the volumes of oral cavity receiving intermediate and high doses may
reduce mucositis incidence.
 2016 The Author(s). Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 120 (2016) 21–27
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Mucositis is a common acute toxicity of head and neck radio-
therapy (RT), which may result in pain, dysphagia [1], weight loss
and aspiration, and reduced quality of life [2]. Mucositis may lead
to missed treatment fractions [3], potentially compromising
locoregional control [4], and is frequently dose-limiting in dose-
escalation and accelerated fractionation regimens designed to
improve tumour control [5]. Moreover, advances in our under-
standing of the mechanisms of ‘‘late” radiation effects have impli-
cated severe acute reactions in the development of these toxicities
[6,7].
There has been a large effort to develop and validate accurate
multifactorial normal tissue complication probability (NTCP) mod-
els (e.g. [8]) for clinical decision-support [9], treatment modality
selection [10] and treatment plan optimisation [11]. However,the prediction of the severity of acute mucositis for individual
patients is highly challenging and there are currently no NTCP
models that can confidently guide clinical decision-making. Dose
objectives, such as those proposed by the Radiation Therapy Oncol-
ogy Group (RTOG) clinical trials, specify varying limits for the
mean dose delivered to the oral cavity in the range of 30–50 Gy
(RTOG 0912, RTOG 0920, RTOG 1216).
It has been hypothesised that one of the major contributing fac-
tors to the suboptimal performance of many NTCP models is an
oversimplified description of the dose distribution [12] using
dose–volume histograms (DVH). Two assumptions are implicit in
this technique. Firstly, each voxel in the organ contributes equally
to a toxicity outcome. Secondly, the spatial distribution of that
dose has no bearing on toxicity. Our group has previously shown
that the spatial distribution of the dose has an impact on toxicity
prediction for both rectal toxicity [13] and xerostomia [14]. We,
therefore, considered that the spatial distribution of the dose might
also play an important role in mucositis. The buccal mucosa is ker-
atinised, whereas other regions of the oral mucosa, such as parts of
22 Acute oral mucositis NTCP modelsthe soft palate and ventral tongue, are not [15], and hence might be
expected to be associated with higher mucositis scores [16].
The two distinct aims of this study were to (i) generate, and val-
idate models for the prediction of the severity of acute oral mucosi-
tis for individual patients to guide clinical decision-making; and
(ii) use those models to establish RT dose–response associations
for severe mucositis that could inform optimal dose-sparing of
the oral mucosa in head and neck RT treatment planning protocols.Materials and methods
Patient data
Data from 351 head and neck RT patients, enrolled in six differ-
ent clinical trials [17–19] (with institutional review board approval
and signed patient consent; details of the trials in Appendix 1),
were available. This builds on a previous study, by our group, based
on data from four phase II clinical trials [20] by incorporating more
data from two phase III trials, in addition to methodological devel-
opments. The patients included in the study encompass a range of
head and neck primary disease sites and RT delivery techniques
and fractionation schedules, thus ensuring a large variation in
the dose distributions across the cohort. Only patients for whom
DICOM RT data were available (351 patients) were included.
Toxicity was consistently scored for all studies using the
clinician-observed oral mucositis score from the Common Termi-
nology Criteria for Adverse Events (CTCAE) versions 2 (mucositis
due to radiation score) [21] or 3 (mucositis/stomatitis (clinical
exam) score) [22] instruments, which are near equivalent. Toxici-
ties were recorded prospectively prior to the start of RT, weekly
during RT, weekly from 1 to 4 weeks post-RT and at 8 weeks
post-RT. No formal quality assurance of these scores (e.g. intra-
and/or inter-observer variability) was undertaken, but all data
were generated by experienced head and neck cancer specialists
working according to standard trial protocols and trained in the
use of the scoring systems. The toxicity endpoint of interest chosen
for analysis was the maximum reported grade and was dichoto-
mised into severe (maximum toxicity score of grade 3 or worse)
and non-severe (maximum toxicity score of less than grade 3)
mucositis. Patients with baseline toxicity were excluded from the
analysis. Patients with missing data and peak grade below 3 were
excluded from the analysis as these patients may have in fact expe-
rienced grade 3 mucositis. Following these inclusion criteria 183
patients were available. Maximum toxicity scores of grade 1, 2
and 3 were experienced by 8 (4%), 41 (22%) and 134 (73%) patients,
respectively.
Relevant clinical data were included as covariates in the models
where available. These were induction chemotherapy (n = 89), con-
current chemotherapy regimen (cisplatin (n = 64), carboplatin
(n = 10), one cycle of cisplatin then one cycle of carboplatin
(n = 6) or none (n = 103)), definitive (n = 152) versus post-
operative RT, primary disease site (nasopharynx (n = 18), orophar-
ynx (n = 100), hypopharynx/larynx (n = 18), parotid gland (n = 39),
unknown primary (n = 8)), age (median = 58 years; range = 17–
88 years) and sex (nmale = 116).Dosimetric data
The oral mucosa was contoured, by clinical oncologists, using
our previously described method [23], which represents the
mucosa by an approximately spherical volume encompassing the
oral cavity (including ‘‘the surfaces of the inner table of mandible,
tongue, base of tongue, floor of mouth and palate”; see Appendix 2
for example). The physical dose distribution was converted to the
fractional dose distribution (physical dose delivered in each frac-
tion) [24], to account for differences in the fractionation schedules.The relative cumulative dose–volume histogram in 20 cGy inter-
vals from 20 to 260 cGy per fraction was inserted as covariates in
the models. 3D moment invariants [10] were calculated, and used
as model covariates, to describe the centre of mass, spread and
skewness of the dose distribution in the three orthogonal direc-
tions (left–right, anterior–posterior, superior–inferior) within the
oral cavity (Appendix 3). Differences in treatment technique (uni-
lateral versus bilateral and conformal versus intensity-modulated
RT (IMRT)) were captured by the dose distributions.Statistical analysis
The statistical analysis used machine learning methods and fol-
lowed the principles suggested by Kang et al. [25] for model gener-
ation and the transparent reporting of a multivariable prediction
model for individual prognosis or diagnosis (TRIPOD) international
consensus guidelines for model evaluation [26]. All RT dose and
clinical covariates were transformed to standardised (Z) scores
(mean = 0, standard deviation = 1) to avoid scale-related feature
dominance. Three different types of classification model: penalised
logistic regression (PLR) [27], support vector classification (SVC)
[28] and random forest classification (RFC) [29] were developed.
Models were generated with (spatial) and without (standard) the
addition of the spatial dose metrics.
Removing covariates based on univariable or stepwise methods
has been extensively shown to result in overfitting (resulting in
models that are not generalisable) and biased parameter estimates
(resulting in misleading associations between covariates and out-
comes) [30–32]. PLR has previously been found to outperform
logistic regression with stepwise variable selection for NTCP mod-
elling studies [33]. Penalisation was performed using ridge regular-
isation [34] or least absolute shrinkage and selection operator
(LASSO) regularisation [27]. These techniques reduce the regres-
sion coefficients, setting some of them to zero (removing that
covariate) in the case of LASSO. SVC models attempt to find a
hyper-plane to separate two outcome classes (in this case severe
and non-severe mucositis) and are able to solve non-linearly sepa-
rable problems (by using non-linear kernels, such as a Gaussian
radial basis function). SVC models with non-linear kernels do not
have intuitive metrics to describe the strength of associations
between covariates and outcome (making them less interpretable
than PLR). RFC models construct an ensemble of decision trees.
They are non-linear, non-parametric and more robust to correlated
covariates than PLR. RFC models provide feature importance mea-
sures, which offer information on the relative strength of associa-
tion between the model covariates and outcome.
The model hyper-parameters were tuned (Appendix 4) and the
generalisability of the models to predict mucositis severity for indi-
vidual patients (aim i) was measured through internal validation
(methods detailed in Appendix 4). The TRIPOD guidelines state that
randomly splitting data into development and validation sets is
erroneously believed to be external validation, but has been shown
to be a ‘‘weak and inefficient form of internal validation”
[26,35,36]. Therefore, all data were used for model generation
and internal validation. Discriminative ability was measured using
area under the receiver operating characteristic curve (AUC). To
make individual patient predictions of the probability of an out-
come good model calibration is important in addition to discrimi-
nation [26]. Model calibration was assessed, using the slope and
intercept of a logistic regression model (without penalisation) of
the actual toxicity outcomes against the predicted probabilities
of severe mucositis (perfect calibration would have a slope of 1
and intercept of 0) [37,38]. The Brier score [39] was calculated to
evaluate the overall model performance (lower values indicate bet-
ter performance) and log loss [40] calculated to assess the model
probability estimates (lower values indicate better probability esti-
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and calibration metrics was used to compare models. This is more
appropriate than formal statistical comparison of AUC, which gives
equal importance weighting to sensitivity and specificity, in the
context of NTCP modelling. Model diagnostics were performed
using learning curves [41] (Appendix 5).
The decision to remove patients with any missing data and
maximum mucositis score less than grade 3 may be considered
overly conservative. For completeness, the modelling of peak
mucositis was repeated, but with the inclusion of patients who
had non-consecutive missing mucositis measurements (increasing
statistical power at the expense of increased potential bias; Appen-
dix 6).
To establish dose–response associations (aim ii), the strength of
the associations between the covariates and severe mucositis were
assessed by bootstrapping (to obtain unbiased confidence inter-
vals) the PLR odds ratios and RFC feature importance measures
for the models with 2000 replicates (model hyper-parameters
were retuned within each bootstrap replicate). For completeness,
the duration of severe mucositis was modelled, using elastic net
regression and random forest regression and the associations
between the model covariates and outcome assessed (Appendix
7). The ‘‘conventional” approach to NTCP modelling considering
both dosimetric and non-dosimetric covariates is to use univari-
able and multivariable (unpenalised) logistic regression. Therefore,
for completeness, this was also performed (Appendix 8).
Results
The average DVH for each mucositis grade is shown in Appendix
9 and demonstrates a clear relationship between dose and toxicity.
The results of the evaluation of the models, using multiple metrics
addressing different aspects of predictive performance, (addressing
aim i) are shown in Table 1 (and Appendix 6). SVC models do not
provide probability estimates and so only discrimination could
be assessed. Attempts were made to convert the SVC model out-
puts to probability estimates using Platt scaling [42]. However, this
led to substantial reductions in AUC (related to the algorithm used;
data not shown). The PLRstandard, SVCstandard and RFCstandard models
had approximately equal discriminative abilities. The addition of
3D moment invariants, describing the spatial distribution of the
dose, did not improve the discriminative ability, or other measures
of predictive performance, of the models. Therefore, the simpler
standard models were favoured. The RFCstandard model had better
calibration, probability estimates and overall performance than
the PLRstandard model so was favoured over the other models, for
prediction of the severity of mucositis for individual patients
(aim i). The RFCstandard model is provided at https://github.com/ja-
miedean/oral-mucositis-model. For completeness, the PLRstandard
model (accounting for covariate transformations to standardised
scores) is given by:
NTCP ¼ e
f
1þ e fTable 1
Performance of models on internal validation.
Model Hyper-parameters Mean AUC (
PLRstandard Regularisation = LASSO, C = 0.1 0.72 (0.09)
SVCstandard Kernel = radial basis function, C = 0.1, gamma = 0.01 0.72 (0.09)
RFCstandard Max depth = 5, max features = square root 0.71 (0.09)
PLRspatial Regularisation = LASSO, C = 0.1 0.72 (0.09)
SVCspatial Kernel = radial basis function, C = 1.0, gamma = 0.001 0.71 (0.09)
RFCspatial Max depth = 5, max features = square root 0.70 (0.09)
PLR – penalised logistic regression; SVC – support vector classification; RFC – random fwhere
f ¼ 0:025 unknownPrimary 0:044
0:205
 
 0:303 parotid 0:209
0:406
 
þ 0:212 V180 53:6
27:5
 
þ 0:194 V220 10:5
11:1
 
where unknownPrimary and parotid are binary and V180 and V220
are given as percentages.
The odds ratios and feature importance measures of the boot-
strapped PLR and RFC model covariates (addressing aim ii), and
confidence intervals (95 percentiles of the bootstrapped values;
non-normal distributions), are displayed in Figs. 1–4. In the PLR
models none of the covariates was significantly associated with
severe mucositis (95 percentiles of the odds ratio not crossing 1).
The correlation matrix for the data (Appendix 10) indicates the
highly correlated nature of the dosimetric data. It should be noted
that logistic regression assumes covariates are independent so the
regression coefficients of correlated covariates are unstable so we
do not recommend using logistic regression to infer dose–response
associations between correlated dose metrics and toxicity (dis-
cussed in Appendix 10). RFC models are more robust to correlated
covariates and, hence, more appropriate for inferring associations
between the correlated dose metrics and severe mucositis. The
covariate with the highest RFC feature importance was V220 in
both RFC models. There was a general trend of increasing feature
importance with increasing dose and feature importance was also
high for RT dose metrics in the range V80–V220. The high fractional
dose–volume parameters, V240 and V260, were either 0% or close
to 0% for nearly all patients (Appendix 9). Therefore, they did not
correlate well with mucositis severity in our dataset. A similar pat-
tern was observed in regression modelling of the duration of severe
mucositis (Appendix 7). Age was the clinical covariate with the
highest feature importance. However, this may be an artefact of
the large number of possible values compared with the other clin-
ical covariates [43]. Age was not significantly associated with sev-
ere mucositis on univariable logistic regression (Appendix 8).
Discussion
We met our first aim of generating and validating predictive
models of severe acute mucositis. The discriminative ability of
the RFCstandard model (and the other models) is modest to good.
The RFCstandard model was better calibrated to the internal valida-
tion data than the PLRstandard model, as demonstrated by having a
calibration slope closer to 1, calibration intercept closer to 0 and
lower log loss, and better overall performance, as indicated by its
lower Brier score. We also met our second aim of determining
associations between RT dose metrics and severe mucositis that
could be used to inform improved RT planning. Regarding aim ii,
we determined that the covariate with the strongest association
with mucositis outcome (peak grade or duration of grade 3) wass.d.) Mean log
loss (s.d.)
Mean Brier
score (s.d.)
Mean calibration
slope (s.d.)
Mean calibration
intercept (s.d.)
0.66 (0.03) 0.23 (0.02) 12.4 (10.9) 5.0 (5.2)
– – – –
0.56 (0.08) 0.19 (0.03) 3.9 (2.2) 1.5 (1.4)
0.66 (0.04) 0.23 (0.02) 11.9 (10.9) 4.8 (5.2)
– – – –
0.56 (0.07) 0.18 (0.03) 4.2 (2.3) 1.9 (1.6)
orest classification; s.d. – standard deviation; C – inverse regularisation strength.
Fig. 1. Bootstrapped (2000 replicates) odds ratios for PLRstandard model. Whiskers show 95 percentiles (non-normal distributions). definitiveRT – definitive radiotherapy
(versus post-operative radiotherapy); indChemo – induction chemotherapy; noConChemo – no concurrent chemotherapy; cisCarbo – one cycle of cisplatin followed by one
cycle of carboplatin; Vx – volume of organ receiving x cGy of radiation per fraction. None of the covariates are significantly associated with severe mucositis.
Fig. 2. Bootstrapped (2000 replicates) odds ratios for PLRspatial model. Whiskers show 95 percentiles (non-normal distributions). definitiveRT – definitive radiotherapy (versus
post-operative radiotherapy); indChemo – induction chemotherapy; noConChemo – no concurrent chemotherapy; cisCarbo – one cycle of cisplatin followed by one cycle of
carboplatin; Vx – volume of organ receiving x cGy of radiation per fraction. None of the covariates are significantly associated with severe mucositis.
24 Acute oral mucositis NTCP modelsthe V220. In interpreting the associations, it is important to note
that they are data-driven. The fact that, for our dataset, the V220
had the strongest association with severe mucositis does not mean
that this dose level has a greater biological effect than higher dose
levels. The variance of the higher dose metrics is lower, as the vol-
umes of oral cavity receiving very high doses are close to 0 for all
patients, and so the covariance for these metrics with severe
mucositis is lower than for V220, which has a higher variance
and covariance (Appendices 9 and 10). We also found associations
between other, intermediate and high, dose levels and severe
mucositis. This indicates that constraining the mean dose deliveredto the oral cavity, as required in RTOG trials, may not be the opti-
mal treatment planning technique to reduce the incidence of sev-
ere mucositis. The mean dose gives equal weighting to all dose
levels. However, our findings, suggest that minimising the volume
of the oral cavity receiving intermediate and high doses as much as
possible would represent a better strategy. We recommend incor-
porating this approach into RT planning, where possible without
compromising other aspects of the plan, such as PTV coverage.
Despite a large number of NTCP models for other toxicities, such
as xerostomia [14,44] and dysphagia [45], and the high incidence
of severe acute mucositis there is a scarcity of models to allow
Fig. 3. Bootstrapped (2000 replicates) feature importance measures for RFCstandard model. Whiskers show 95 percentiles (non-normal distributions). definitiveRT – definitive
radiotherapy (versus post-operative radiotherapy); indChemo – induction chemotherapy; noConChemo – no concurrent chemotherapy; cisCarbo – one cycle of cisplatin
followed by one cycle of carboplatin; Vx – volume of organ receiving x cGy of radiation per fraction. The feature importance of the dose metrics increases with increasing dose
up to V220, which has the highest feature importance of any covariate.
Fig. 4. Bootstrapped (2000 replicates) feature importance measures for RFCspatial model. Whiskers show 95 percentiles (non-normal distributions). definitiveRT – definitive
radiotherapy (versus post-operative radiotherapy); indChemo – induction chemotherapy; noConChemo – no concurrent chemotherapy; cisCarbo – one cycle of cisplatin
followed by one cycle of carboplatin; Vx – volume of organ receiving x cGy of radiation per fraction. The feature importance of the dose metrics increases with increasing dose
up to V220, which has the highest feature importance of any covariate.
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cols. This study improved upon our previous findings [20] due to
far greater variation in the RT dose distributions in the patient
cohort included (as a result of including patients from the PAR-
SPORT and COSTAR trials) and a more rigorous statistical explo-
ration. The wide range of dose distributions increases the
generalisability of the models and reduces the chance of introduc-
ing biases, for example, due to the primary tumour location. Only
one other model of severe acute mucositis resulting from IMRT
has been published [46]. This study made a similar finding to ourdose–response association (aim ii) that the volume of oral mucosa
(defined as oral cavity, oropharynx and hypopharynx) receiving
10.1 Gy per week (2.0 Gy per daily fraction) was most strongly
associated with severe mucositis. The authors also found a positive
correlation between concurrent chemotherapy and severe mucosi-
tis, unlike our study, which found no significant association. A pos-
sible explanation is that, in our dataset, concurrent chemotherapy
was positively correlated with the dose–volumemetrics (Appendix
10) so the RT dose effects may mask the effects of concurrent
chemotherapy. This is largely due to the fact that all of the parotid
26 Acute oral mucositis NTCP modelsgland tumour patients received unilateral irradiation (less dose
delivered to the oral cavity) and did not receive concurrent
chemotherapy (Appendix 1). It is also likely that the effect of
chemotherapy is insufficiently characterised (using binary covari-
ates) in our analysis. The numbers of patients receiving carboplatin
or one cycle of cisplatin followed by one cycle of carboplatin are
likely too small to be able to detect any significant associations.
Our study features several limitations. The current delineation
technique used to contour the oral mucosa does not provide an
anatomically accurate representation of the mucosal surfaces
within the oral cavity, but instead an oral cavity volume. A large
amount of this volume is the musculature of the tongue and not
mucosa. Additionally, the volume does not encompass all of the
oral mucosal surfaces, such as the buccal mucosa. This may also
have contributed to the lack of increased predicted performance
with the addition of spatial dose metrics. Lack of standardised
guidelines for accurately delineating the oral mucosa may have
contributed to the scarcity of oral mucositis NTCP models. We have
recently validated a method of automatically contouring the oral
mucosal surfaces in a more anatomically realistic manner
[47,48]. We intend to use this approach in future analyses and
determine whether characterising the mucosal dose distributions
in this manner improves the predictive power of our NTCP model.
It should be noted that the CTCAE clinical mucositis scoring system
does not capture the morphological extent of the mucositis. There-
fore, the spatial metrics have the potential to be sensitive to regio-
nal variations in the radiosensitivity of the oral mucosa, but not the
morphological extent of the mucositis. Additionally, there are fac-
tors that are likely to contribute to mucositis, but could not be
analysed, as insufficient or no data were available. Tobacco and
alcohol use were not collected in the PARSPORT or COSTAR trials,
so were not included in the analysis. Genetic predispositions to
severe (chemo)radiation-induced toxicity are also expected.
Finally, our models have not been externally validated. We suggest
that their discrimination and calibration are evaluated in different
cohorts of patients to better assess their generalisability.
In conclusion, we have (i) generated and validated NTCP models
for the prediction of the severity of acute mucositis for individual
patients with modest to good discrimination and (ii) established
RT dose–response associations for severe mucositis. We found that
a RFC model incorporating clinical and DVH data provided equal
discriminative ability to, and better calibration than, PLR and SVC
models and represents a promising foundation for a clinical
decision-support tool for individual patient management. We
demonstrated an association between volumes of oral cavity
receiving intermediate and high doses and severe mucositis and,
hence, recommend that these should be minimised where possible
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